Clinical Utility of Synuclein Skin Biopsy in the Initial Diagnosis and Evaluation of Parkinsonian Disorders
Objective: To determine the clinical utility of phosphorylated alpha-synuclein (P-SYN) within skin biopsies in diagnostic and management decisions. Background: The initial diagnosis of Parkinson’s Disease…The Purely Thermodynamic Anti-prionic Mode of Action for the Treatment of Parkinson’s Disease and other Neurodegenerative Diseases
Objective: Demonstration of the anti-prionic MoA for α-synuclein in vitro, PoC in vivo, as well as ex vivo. Background: Neurodegenerative protein-misfolding diseases, like Alzheimer’s (AD)…Discriminating alpha-synuclein strains in Parkinson’s disease
Objective: To evaluate possible differences in the biological properties of alpha-synuclein fibrils derived from different patients with Parkinson's disease. Background: Parkinson’s disease (PD) is a…V-ATPase subunit V1G1 overexpression conferred the mice neuroprotection during MPTP exposure
Objective: Elucidating the role of lysosomal dysfunction due to altered stability and expression levels of V-type proton ATPase subunit G (V1G1) in the degradation and…Impaired lysophagy function exacerbates propagation of α-synuclein aggregation
Objective: We aimed to clarify how exogenous αSyn aggregates interact with native αSyn in the cytoplasm and seed aggregation, and what defense mechanisms protect against…Pathological findings in a case of DJ-1 early onset Parkinson’s disease
Objective: To report the postmortem findings in a case of early onset genetically confirmed DJ-1 (PARK7) PD. Background: As a very rare cause (1-2%) of…Glunomab: a novel therapeutics for the treatment of Parkinson’s Disease
Objective: The focus of this study was: 1) to characterize the expression and the localization of an endogenous protease, tissue plasminogen activator (tPA) in the…Evaluation of small extracellular vesicles derived miRNA as biomarkers for Parkinson’s disease: comparison with plasma miRNA
Objective: To identify differentially expressed small extracellular vesicles (sEV) derived miRNAs in Parkinson’s disease using small RNA-sequencing and to evaluate their potential as biomarker targets.…IP-RT-QuIC Identify Disease-Specific Alpha-Synuclein Seeds in serum from patients with syncleinopathy
Objective: To examine whether alpha-synuclein (aSyn) seed exists in the serum and its potential as a serum biomarker. Background: Parkinson’s disease (PD) and Multiple system…Glucocerebrosidase (GCase) activator, Ambroxol, reduces alpha-synuclein serine-129 phosphorylation and oligomers in mutant LRRK2 R1441G mouse brains
Objective: To explore whether inducing brain GCase activity by Ambroxol™ (ABX; a brain-penetrant GCase activator) can reduce a-synuclein (αSyn) serine-129 phosphorylation and oligomer accumulation in…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 51
- Next Page »